1. Home
  2. TIPT vs DCTH Comparison

TIPT vs DCTH Comparison

Compare TIPT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiptree Inc.

TIPT

Tiptree Inc.

HOLD

Current Price

$17.55

Market Cap

672.9M

Sector

Finance

ML Signal

HOLD

DCTH

Delcath Systems Inc.

HOLD

Current Price

$16.13

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIPT
DCTH
Founded
2007
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.9M
578.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
TIPT
DCTH
Price
$17.55
$16.13
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$22.00
AVG Volume (30 Days)
155.0K
353.8K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
1.40%
N/A
EPS Growth
N/A
107.53
EPS
0.34
0.04
Revenue
$488,000.00
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
$51.59
$406.25
Revenue Growth
N/A
N/A
52 Week Low
$15.49
$8.12
52 Week High
$27.38
$17.42

Technical Indicators

Market Signals
Indicator
TIPT
DCTH
Relative Strength Index (RSI) 39.34 52.64
Support Level $17.32 $15.68
Resistance Level $18.72 $17.42
Average True Range (ATR) 0.29 0.40
MACD -0.09 -0.14
Stochastic Oscillator 16.85 39.96

Price Performance

Historical Comparison
TIPT
DCTH

About TIPT Tiptree Inc.

Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: